SAN FRANCISCO–(BUSINESS WIRE)–#DNA–Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced several presentations at SynBioBeta 2019, the leading industry conference bringing together biological engineers, investors, innovators and entrepreneurs to build a better world with biology, to be held October 1-3 in San Francisco, California.
Twist’s presence at the meeting includes:
- Tuesday, October 1, 2019, 2:30pm, Bill Peck, Ph.D., Chief Technology Officer and Co-Founder of Twist Bioscience on DNA data storage
- Tuesday, October 1, 2019, 5:30pm, Aaron Sato, Ph.D., Chief Scientific Officer, Twist Biopharma, a division of Twist Bioscience on biopharma antibody discovery
- Wednesday, October 2, 2019, 1:30pm, Emily Leproust, Ph.D., CEO and Co-Founder of Twist Bioscience on the company
- Thursday, October 3, 2019, 12:30pm, Rebecca Nugent, Ph.D., Director of Research and Development, Twist Bioscience on redesigning the research funnel
- Booth #225 in the Exhibit Hall
“Growth in synthetic biology’s technology, investment, talent, and innovation has continued to skyrocket over the past year, and we are so excited to see this year’s conference, bringing together all the most important players in the industry,” said SynBioBeta founder and CEO John Cumbers. “Synthetic biology is ready to turn today’s industry on its head and revolutionize the way we do business. In the same way that every company today is in some way an internet company, every company will one day be a biology company. SynBioBeta 2019 is the place to get ahead of the curve.”
SynBioBeta is the leading community of innovators, investors, engineers, and thinkers who share a passion for using synthetic biology to build a better, more sustainable universe. We create and energize innovation communities to make the impossible possible via unparalleled opportunities for growth, networking, storytelling, and learning.
Through international synthetic biology conferences and events that bring the entire community together throughout the year, we give innovators the opportunity to meet with other bright minds building and shaping the bioeconomy. We showcase cutting-edge synthetic biology research and technologies that are transforming how we feed, fuel, heal, and build the world.
SynBioBeta offers a weekly industry digest, a podcast, a quarterly magazine (coming soon), and educational courses, in addition to providing our world-class industry partners with opportunities for advertising, partnership, trade show exhibition, strategic consultation, and promotion opportunities. For more information, visit www.synbiobeta.com.
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.
Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties of the ability to attract new customers and retain and grow sales from existing customers; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology could make the products Twist Bioscience is developing obsolete or non-competitive; uncertainties of the retention of a significant customer; risks of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate Twist Bioscience’s patents or proprietary rights; and the risk that Twist Bioscience’s proprietary rights may be insufficient to protect its technologies. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist Bioscience’s business in general, see Twist Bioscience’s risk factors set forth in Twist Bioscience’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 9, 2019. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.